President Donald Trump on Thursday unveiled a new pharmaceutical trade crackdown, imposing tariffs of up to 100% on imported branded drugs from companies that have not agreed to lower U.S. prices or move production into the United States, escalating his long-running effort to pressure the drug industry on costs.
The measure, announced in a White House proclamation dated April 2, frames foreign dependence for patented medicines and pharmaceutical ingredients as a national security risk.
